(Q52854227)

8 May 2018

title

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. (English)

1 reference

8 May 2018

0 references

1 reference

1 reference

1

1 reference

8 May 2018

Paolo Ghia

5

1 reference

8 May 2018

Dolors Colomer

8

1 reference

8 May 2018

author name string

Villamor N

2

1 reference

8 May 2018

Ritgen M

3

1 reference

8 May 2018

Böttcher S

4

1 reference

8 May 2018

Zehnder JL

6

1 reference

8 May 2018

Lozanski G

7

1 reference

8 May 2018

Moreno C

9

1 reference

8 May 2018

Geuna M

10

1 reference

8 May 2018

Evans PA

11

1 reference

8 May 2018

Natkunam Y

12

1 reference

8 May 2018

Coutre SE

13

1 reference

8 May 2018

Avery ED

14

1 reference

8 May 2018

Rassenti LZ

15

1 reference

8 May 2018

Kipps TJ

16

1 reference

8 May 2018

Caligaris-Cappio F

17

1 reference

8 May 2018

Kneba M

18

1 reference

8 May 2018

Byrd JC

19

1 reference

8 May 2018

Hallek MJ

20

1 reference

8 May 2018

Montserrat E

21

1 reference

8 May 2018

Hillmen P

22

1 reference

8 May 2018

publication date

15 March 2007

1 reference

8 May 2018

published in

Leukemia

1 reference

8 May 2018

volume

21

1 reference

8 May 2018

issue

5

1 reference

8 May 2018

page(s)

956-964

1 reference

8 May 2018

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Evaluation of Residual Disease in B-Cell Chronic Lymphocytic Leukemia Patients in Clinical and Bone-Marrow Remission Using CD5-CD19 Markers and PCR Study of Gene Rearrangements

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Apparent modulation of CD20 by rituximab: an alternative explanation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404584

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404584

1 reference

8 May 2018

1 reference

8 May 2018